Researchers at the University of Guadalajara, Mexico have shown in a preclinical trial that β-Caryophylene extracted from cannabis has a multiple effect against type 1 diabetes and other sequelae of this condition.
Β-Caryophylene is one of the aromatic components of plants known as terpenes. Among them: rosemary, thyme, eucalyptus and cannabis.
The researchers noted that this terpene also has an effect to generate well-being during diabetes.
Síguenos en instagram: @mcnglobal
“The study aimed to measure the effect of regulating the glucose rhythm of neuropathic pain and also of depression mainly in mice of the Balb / c strain.” said CUCEI researcher Dalia Aguilar.
To do this, the researchers induced diabetes in rodents. In particular they used the molecule known as streptozotocin known for its destructive activity of blood sugar bearing cells.
Three groups of rodents were studied: one of control, another induced by diabetes and a last one that was induced beta-Caryophyll extracted a cannabis sample.
“We were able to observe that those mice that were treated with beta-Caryophylene for 45 days with an administration of 10 mg / kg of this substance, decreased neuropathic pain, depression that is induced or directly related to the development of neuropathic pain. “
“We observed that the mice with diabetes had a greater mobility with respect to the control group and also that the group treated with β-Caryophylene that was diabetic had a reversal of this mobility, that is, it decreases this condition.”
On blood glucose concentration, it was observed that rodents who had diabetes in 70%.
Another advantage highlighted by the researchers is that with β-Caryophylene, diabetes could be treated at a lower cost than conventional treatments.
Read the research here: http://bit.ly/2kjZykz
in Costa Rica. 
